| Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ... New England Journal of Medicine 363 (18), 1693-1703, 2010 | 5492 | 2010 |
| Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK AT Shaw, BY Yeap, M Mino-Kenudson, SR Digumarthy, DB Costa, ... Journal of clinical oncology 27 (26), 4247-4253, 2009 | 2464 | 2009 |
| Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer AT Shaw, SHI Ou, YJ Bang, DR Camidge, BJ Solomon, R Salgia, GJ Riely, ... New England Journal of Medicine 371 (21), 1963-1971, 2014 | 2219 | 2014 |
| Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study DR Camidge, YJ Bang, EL Kwak, AJ Iafrate, M Varella-Garcia, SB Fox, ... The lancet oncology 13 (10), 1011-1019, 2012 | 1555 | 2012 |
| Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints S Koyama, EA Akbay, YY Li, GS Herter-Sprie, KA Buczkowski, ... Nature communications 7 (1), 10501, 2016 | 1507 | 2016 |
| Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ... The lancet oncology 12 (11), 1004-1012, 2011 | 1149 | 2011 |
| Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases DB Costa, AT Shaw, SHI Ou, BJ Solomon, GJ Riely, MJ Ahn, C Zhou, ... Journal of Clinical Oncology 33 (17), 1881-1888, 2015 | 687 | 2015 |
| Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M–positive lung cancer and acquired resistance to osimertinib GR Oxnard, Y Hu, KF Mileham, H Husain, DB Costa, P Tracy, N Feeney, ... JAMA oncology 4 (11), 1527-1534, 2018 | 669 | 2018 |
| CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib DB Costa, S Kobayashi, SS Pandya, WL Yeo, Z Shen, W Tan, KD Wilner Journal of Clinical Oncology 29 (15), e443-e445, 2011 | 665 | 2011 |
| EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications H Yasuda, S Kobayashi, DB Costa The lancet oncology 13 (1), e23-e31, 2012 | 635 | 2012 |
| RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer MJ Niederst, LV Sequist, JT Poirier, CH Mermel, EL Lockerman, ... Nature communications 6 (1), 6377, 2015 | 612 | 2015 |
| Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer H Yasuda, E Park, CH Yun, NJ Sng, AR Lucena-Araujo, WL Yeo, ... Science translational medicine 5 (216), 216ra177-216ra177, 2013 | 586 | 2013 |
| BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations DB Costa, B Halmos, A Kumar, ST Schumer, MS Huberman, TJ Boggon, ... PLoS medicine 4 (10), e315, 2007 | 582 | 2007 |
| Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancers dependent on the epidermal growth factor receptor pathway KSH Nguyen, S Kobayashi, DB Costa Clinical lung cancer 10 (4), 281-289, 2009 | 574 | 2009 |
| A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response Z Chen, K Cheng, Z Walton, Y Wang, H Ebi, T Shimamura, Y Liu, ... Nature 483 (7391), 613-617, 2012 | 504 | 2012 |
| Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers D Rangachari, N Yamaguchi, PA VanderLaan, E Folch, A Mahadevan, ... Lung cancer 88 (1), 108-111, 2015 | 496 | 2015 |
| Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non–small-cell lung cancer LV Sequist, J Von Pawel, EG Garmey, WL Akerley, W Brugger, D Ferrari, ... Journal of Clinical Oncology 29 (24), 3307-3315, 2011 | 468 | 2011 |
| Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib … S Heon, BY Yeap, GJ Britt, DB Costa, MS Rabin, DM Jackman, ... Clinical cancer research 16 (23), 5873-5882, 2010 | 271 | 2010 |
| Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non–Small-Cell Lung Cancer: Results From PROFILE 1014 BJ Solomon, F Cappuzzo, E Felip, FH Blackhall, DB Costa, DW Kim, ... Journal of Clinical Oncology 34 (24), 2858-2865, 2016 | 266 | 2016 |
| Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer AF Farago, LP Le, Z Zheng, A Muzikansky, A Drilon, M Patel, TM Bauer, ... Journal of Thoracic Oncology 10 (12), 1670-1674, 2015 | 234 | 2015 |
Susumu S. KobayashiBeth Israel Deaconess Medical CenterE-mail confirmado em bidmc.harvard.edu
